Sunesis Pharmaceuticals

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PRA Health Sciences

Poseida Therapeutics

Salarius Pharmaceuticals Inc

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC.

Why Sunesis, Poseida, Salarius And PRA Health Are Rallying

The stock price of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) increased by over 65% during intraday trading. This is why it happened.

SNSS Stock Price Increased Over 65% Intraday: Why It Happened

An analyst upgrade is the near-term catalyst, but for Sunesis Pharmaceuticals, it's really about patents in oncology and an impending merger with Viracta. The post SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today appeared first on InvestorPlace.

SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today

The stock price of Sunesis Pharmaceuticals, Inc (NASDAQ: SNSS) increased by over 46% during intraday trading. This is why it happened.

SNSS Stock Price Increased Over 46% Intraday: Why It Happened

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u

SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible breaches of fiduciary duties and other violations of law related to Sunesis' agreement to merge with Viracta Therapeutics, Inc. (“Viracta”). Under the terms of the agreement, Sunesis will issue a number of shares of Sunesis common stock to stockholders of Viracta.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Sunesis Pharmaceuticals, Inc. Merger

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. ("Sunesis " or the "Company") (NASDAQ: SNSS) in connection with the Company's proposed merger...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) and Viracta Therapeutics, Inc. is fair to Sunesis shareholders. Halper Sadeh encourages Sunesis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Under the terms of the merger agreement, Viracta

Sunesis Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sunesis Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SNSS

Shares of SNSS stock are climbing higher on Monday after Sunesis Pharmaceuticals announced a merger deal with Viracta Therapeutics. The post Sunesis Pharmaceuticals News: 7 Things for SNSS Stock Investors to Know About the Viracta Deal appeared first on InvestorPlace.

Sunesis Pharmaceuticals News: 7 Things for SNSS Stock Investors to Know About the Viracta Deal

Merger to c reate Nasdaq-listed company focused on developing Viracta's precision oncology pipeline targeting virus-associated malignancies

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Sunesis Pharmaceuticals, Inc. (SNSS) Q3 2020 Results - Earnings Call Transcript

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020.

Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

The drugmaker is having to take a last-resort measure to keep its shares listed on the Nasdaq stock exchange.

Why Sunesis Pharmaceuticals Stock Is Sinking Today

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.

Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m. Eastern Time today. The reverse stock split was effected by Sunesis in accordance with the authorization, and within the split ratio range, adopted by Sunesis stockholders at the 2020 Annual Meeting of Stockholders held on June 16, 2020.

Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q2 2020 Results - Earnings Call Transcript

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) were down 4.45% in after-market trading after the company reported Q2 results.

Recap: Sunesis Pharmaceuticals Q2 Earnings

Sunesis (SNSS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Sunesis Pharmaceuticals (SNSS) Reports Q2 Loss, Misses Revenue Estimates

Sunesis Pharmaceuticals (NASDAQ: SNSS) will be releasing its next round of earnings this Tuesday, August 11.

Earnings Preview for Sunesis Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020.

Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23.

News for Sunesis Pharmaceuticals Stock (SNSS)